Skip to main content
. 2022 May 23;7(10):e158856. doi: 10.1172/jci.insight.158856

Figure 4. Chronic treatment with EPO but not with a nonerythropoietic EPOR agonist ARA290 prolongs heart graft survival.

Figure 4

(A) Schematic of treatment protocol for maintenance EPO administration. (B) Kaplan-Meier survival analysis of BALB/c hearts transplanted into CTLA4-Ig–treated recipients plus EPO either peritransplant or 3 times per week until day 60 (maintenance). (C) Representative photomicrograph of H&E-stained allograft from a recipient given chronic maintenance EPO through day 60 and harvested on day 90 after transplant, showing diffuse mononuclear cell infiltration consistent with rejection (scale bar: 200 μm). (D) Schematic of treatment protocol for ARA290 administration. (E) Kaplan-Meier survival analysis of BALB/c hearts transplanted into CTLA4-Ig–treated recipients plus ARA290 3 times per week. **P < 0.01; ***P < 0.001; NS, not significant.